Benzinga | May 19, 2021 08:05AM EDT

aTyr Pharma Highlights Presentation Preclinical Research Highlighting 'Mechanistic Insights Into Tumor Inhibitory Effects Of ATYR2810'

aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia on Cancer Stem Cells: Advances in Biology and Clinical Translation, which is being held May 19 -- 21, 2021. The abstract and poster are available on the Keystone Symposia website.

The poster presents preclinical findings demonstrating that ATYR2810, a Neuropilin-2 (NRP2) antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes patient-derived xenograft models of triple-negative breast cancer (TNBC) to chemotherapy. Furthermore, gene expression data from TNBC xenograft samples and patient derived organoids show that ATYR2810 downregulates several cancer stem cell and epithelial-mesenchymal transition (EMT) markers.

Details of the abstract and poster presentation are as follows:

Title: ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy

Authors: Yeeting E. Chong, Zhiwen Xu, Hira Lal Goel, Alison G. Barber, Christoph Burkart, Luke Burman, Kaitlyn Rauch, Justin Rahman, Arthur M. Mercurio, Leslie A. Nangle. aTyr Pharma, San Diego, CA, University of Massachusetts Medical School, Boston, MA.

Session: Poster Session 1

Live Q&A Date and Time: May 19, 2021, 2:30 -- 3:00pm ET

The poster is also available on the aTyr website.